Drug Trial Radar · NCT05332821
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,244
Actual
Start
Dec 28, 2022
Primary completion
Jul 30, 2023
Study completion Jan 10, 2024
Sponsor
- Lead sponsor
- Zhongda HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 18, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage hepatocellular carcinoma (HCC).
Conditions
- Hepatocellular Carcinoma
Interventions
PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumabDrug
PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
TACEProcedure
TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival(OS)Time frame: up to approximately 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Gao-Jun Teng
Nanjing, China
Zheng-Gang Ren
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.